Quarterly ResultJul 29, 2026, 04:09 PM
Integra LifeSciences Q2 Net Income $4.48M; H1 Revenue $810.7M
AI Summary
Integra LifeSciences reported Q2 2026 net income of $4.48 million, a significant improvement from a $484.07 million net loss in Q2 2025, which included a substantial goodwill impairment. For the first half of 2026, total revenue increased by 1.6% to $810.68 million, with net loss narrowing to $0.13 million from $509.37 million in the prior year. The company also recognized a $19.0 million IEEPA tariff refund receivable and updated segment names.
Key Highlights
- Q2 2026 net income was $4.48 million, up from a $484.07 million net loss in Q2 2025.
- Q2 2026 total revenue increased 0.8% to $418.76 million from $415.61 million in Q2 2025.
- H1 2026 total revenue grew 1.6% to $810.68 million from $798.26 million in H1 2025.
- H1 2026 net loss narrowed to $0.13 million from a $509.37 million net loss in H1 2025.
- H1 2026 operating cash flow was $32.61 million, compared to a $2.34 million outflow in H1 2025.
- Recognized a $19.0 million IEEPA tariff refund receivable in Q1 2026.
- Specialty Surgery segment revenue increased 1.75% to $309.27 million in Q2 2026.
- Tissue Reconstruction segment revenue decreased 1.93% to $109.49 million in Q2 2026.
Price Impact
More from IART